File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Methotrexate versus traditional Chinese medicine in psoriasis: A randomized, placebo-controlled trial to determine efficacy, safety and quality of life

TitleMethotrexate versus traditional Chinese medicine in psoriasis: A randomized, placebo-controlled trial to determine efficacy, safety and quality of life
Authors
Issue Date2010
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CED
Citation
Clinical And Experimental Dermatology, 2010, v. 35 n. 7, p. 717-722 How to Cite?
AbstractBackground. Psoriasis is a common and chronic immune-mediated skin disorder, for which there is currently no cure. To our knowledge, this is the first randomized placebo-controlled trial comparing methotrexate and traditional Chinese medicine (TCM) in terms of efficacy, safety, and quality of life for the treatment of psoriasis. Methods. In total, 61 patients with moderate to severe plaque psoriasis were randomized to receive treatment with methotrexate, TCM or placebo for 6 months. The primary outcome measure was the Psoriasis Area and Severity Index (PASI), and secondary outcome measures were the Physician's Global Assessment (PGA) and the Psoriasis Disability Index (PDI). Results. In all, 50 patients completed the study and were included in the analysis. Dropout rates were highest in the TCM group. Mean PASI change from baseline at 6 months revealed an improvement of 73.9% of the methotrexate group, 15.1% of the TCM group and 32.0% of the placebo group. There was a significant difference between the three groups, with methotrexate showing greater effectiveness than the other two groups. No significant difference was found between the TCM and placebo groups. The methotrexate group also had greater improvement when assessed using the PGA and PDI. Conclusions. Our results verify the therapeutic effect of methotrexate for the management of psoriasis. Despite widespread belief and use of TCM in Asia for the treatment of psoriasis, we were unable to confirm the efficacy of TCM in this study. © 2009 British Association of Dermatologists.
Persistent Identifierhttp://hdl.handle.net/10722/144282
ISSN
2015 Impact Factor: 1.315
2015 SCImago Journal Rankings: 0.550
ISI Accession Number ID
Funding AgencyGrant Number
Clinical Centre for Teaching and Research in Chinese Medicine, Tung Wah Hospital, University of Hong Kong
Funding Information:

We thank Professor H. C. Liu and his team from the Clinical Centre for Teaching and Research in Chinese Medicine, Tung Wah Hospital, University of Hong Kong, for their kind collaboration and support of this study.

References

 

DC FieldValueLanguage
dc.contributor.authorHo, SGYen_HK
dc.contributor.authorYeung, CKen_HK
dc.contributor.authorChan, HHLen_HK
dc.date.accessioned2012-01-20T08:59:31Z-
dc.date.available2012-01-20T08:59:31Z-
dc.date.issued2010en_HK
dc.identifier.citationClinical And Experimental Dermatology, 2010, v. 35 n. 7, p. 717-722en_HK
dc.identifier.issn0307-6938en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144282-
dc.description.abstractBackground. Psoriasis is a common and chronic immune-mediated skin disorder, for which there is currently no cure. To our knowledge, this is the first randomized placebo-controlled trial comparing methotrexate and traditional Chinese medicine (TCM) in terms of efficacy, safety, and quality of life for the treatment of psoriasis. Methods. In total, 61 patients with moderate to severe plaque psoriasis were randomized to receive treatment with methotrexate, TCM or placebo for 6 months. The primary outcome measure was the Psoriasis Area and Severity Index (PASI), and secondary outcome measures were the Physician's Global Assessment (PGA) and the Psoriasis Disability Index (PDI). Results. In all, 50 patients completed the study and were included in the analysis. Dropout rates were highest in the TCM group. Mean PASI change from baseline at 6 months revealed an improvement of 73.9% of the methotrexate group, 15.1% of the TCM group and 32.0% of the placebo group. There was a significant difference between the three groups, with methotrexate showing greater effectiveness than the other two groups. No significant difference was found between the TCM and placebo groups. The methotrexate group also had greater improvement when assessed using the PGA and PDI. Conclusions. Our results verify the therapeutic effect of methotrexate for the management of psoriasis. Despite widespread belief and use of TCM in Asia for the treatment of psoriasis, we were unable to confirm the efficacy of TCM in this study. © 2009 British Association of Dermatologists.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEDen_HK
dc.relation.ispartofClinical and Experimental Dermatologyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshDermatologic Agents - adverse effects - therapeutic useen_HK
dc.subject.meshDisability Evaluationen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshDrugs, Chinese Herbal - adverse effects - therapeutic useen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunosuppressive Agents - adverse effects - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMethotrexate - adverse effects - therapeutic useen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPsoriasis - drug therapy - rehabilitationen_HK
dc.subject.meshQuality of Lifeen_HK
dc.subject.meshSeverity of Illness Indexen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleMethotrexate versus traditional Chinese medicine in psoriasis: A randomized, placebo-controlled trial to determine efficacy, safety and quality of lifeen_HK
dc.typeArticleen_HK
dc.identifier.emailHo, SGY:gyho@hku.hken_HK
dc.identifier.authorityHo, SGY=rp01573en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1365-2230.2009.03693.xen_HK
dc.identifier.pmid19925489-
dc.identifier.scopuseid_2-s2.0-77956679987en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77956679987&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume35en_HK
dc.identifier.issue7en_HK
dc.identifier.spage717en_HK
dc.identifier.epage722en_HK
dc.identifier.eissn1365-2230-
dc.identifier.isiWOS:000281708900007-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHo, SGY=35205331800en_HK
dc.identifier.scopusauthoridYeung, CK=7201354123en_HK
dc.identifier.scopusauthoridChan, HHL=24555248900en_HK
dc.identifier.citeulike7872284-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats